Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety.

Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney J Jr, Cremers SC, Bilezikian JP.

J Clin Endocrinol Metab. 2013 Jan;98(1):137-44. doi: 10.1210/jc.2012-2984.

2.

Therapy of hypoparathyroidism with intact parathyroid hormone.

Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP.

Osteoporos Int. 2010 Nov;21(11):1927-34. doi: 10.1007/s00198-009-1149-x.

3.

Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.

Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr.

J Clin Endocrinol Metab. 2010 Jun;95(6):2680-8. doi: 10.1210/jc.2009-2464.

4.

Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.

Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP.

J Clin Endocrinol Metab. 2016 Jul;101(7):2742-50. doi: 10.1210/jc.2015-4135.

PMID:
27144931
5.

The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.

Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L; Hypoparathyroid Study Group..

J Bone Miner Res. 2011 Oct;26(10):2358-70. doi: 10.1002/jbmr.470.

6.

PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.

Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F, Raggiunti B, Volpe R, Manfrini S, Vescini F; Hypoparathyroidism AME Group..

J Clin Endocrinol Metab. 2015 Sep;100(9):3590-7. doi: 10.1210/jc.2015-1855.

PMID:
26196949
7.

Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.

Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler GB Jr.

J Clin Endocrinol Metab. 2012 Feb;97(2):391-9. doi: 10.1210/jc.2011-1908. Erratum in: J Clin Endocrinol Metab. 2015 Jul;100(7):2800.

8.

PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.

Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L.

J Bone Miner Res. 2013 Oct;28(10):2232-43. doi: 10.1002/jbmr.1964.

9.

Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.

Gafni RI, Brahim JS, Andreopoulou P, Bhattacharyya N, Kelly MH, Brillante BA, Reynolds JC, Zhou H, Dempster DW, Collins MT.

J Bone Miner Res. 2012 Aug;27(8):1811-20. doi: 10.1002/jbmr.1627.

10.

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP.

J Clin Endocrinol Metab. 2000 Sep;85(9):3069-76.

PMID:
10999788
11.

Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement.

Rubin MR, Bilezikian JP.

Arq Bras Endocrinol Metabol. 2010 Mar;54(2):220-6.

12.

Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.

Gafni RI, Guthrie LC, Kelly MH, Brillante BA, Christie CM, Reynolds JC, Yovetich NA, James R, Collins MT.

J Bone Miner Res. 2015 Nov;30(11):2112-8. doi: 10.1002/jbmr.2555.

13.

Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.

Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H.

Clin Ther. 2014 May;36(5):722-36. doi: 10.1016/j.clinthera.2014.04.001.

14.

Use of parathyroid hormone in hypoparathyroidism.

Cusano NE, Rubin MR, Irani D, Sliney J Jr, Bilezikian JP.

J Endocrinol Invest. 2013 Dec;36(11):1121-7. Review.

15.

Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83. doi: 10.1016/S2213-8587(13)70106-2. Erratum in: Lancet Diabetes Endocrinol. 2014 Jan;2(1):e3. Dosage error in article text.

PMID:
24622413
16.

Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.

Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr.

J Clin Endocrinol Metab. 2003 Sep;88(9):4214-20.

PMID:
12970289
17.

Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone.

Duan Y, De Luca V, Seeman E.

J Clin Endocrinol Metab. 1999 Feb;84(2):718-22.

PMID:
10022443
18.

Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism.

Laway BA, Goswami R, Singh N, Gupta N, Seith A.

Clin Endocrinol (Oxf). 2006 Apr;64(4):405-9.

PMID:
16584512
19.

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.

J Clin Endocrinol Metab. 2004 Jul;89(7):3319-25.

PMID:
15240609
20.

Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.

Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA.

Osteoporos Int. 2013 Apr;24(4):1503-11. doi: 10.1007/s00198-012-2098-3.

Items per page

Supplemental Content

Support Center